![logo](/logos/300813.SZ.webp)
Zhejiang Tailin BioEngineering Co.,Ltd
SZSE:300813.SZ
24.27 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 269.856 | 373.878 | 283.248 | 200.238 | 180.928 | 159.098 | 142.018 | 111.761 | 82.333 | 59.5 | 94.463 |
Cost of Revenue
| 135.682 | 177.271 | 107.979 | 74.352 | 76.788 | 63.204 | 56.337 | 45.959 | 33.09 | 22.932 | 37.722 |
Gross Profit
| 134.174 | 196.607 | 175.27 | 125.886 | 104.14 | 95.894 | 85.681 | 65.802 | 49.243 | 36.567 | 56.741 |
Gross Profit Ratio
| 0.497 | 0.526 | 0.619 | 0.629 | 0.576 | 0.603 | 0.603 | 0.589 | 0.598 | 0.615 | 0.601 |
Reseach & Development Expenses
| 58.404 | 64.468 | 55.048 | 37.722 | 29.31 | 21.148 | 15.524 | 27.084 | 9.788 | 10.311 | 11.039 |
General & Administrative Expenses
| 8.282 | 11.196 | 7.364 | 9.126 | 5.37 | 3.097 | 2.516 | -18.693 | 5.952 | 1.968 | 2.594 |
Selling & Marketing Expenses
| 45.038 | 42.917 | 39.141 | 31.107 | 25.794 | 19.657 | 16.929 | 14.191 | 12.26 | 9.529 | 10.959 |
SG&A
| 53.32 | 54.113 | 46.505 | 40.233 | 31.164 | 22.754 | 19.445 | -4.502 | 18.212 | 11.497 | 13.553 |
Other Expenses
| 0.197 | 0.335 | -0.149 | -0.203 | 0.212 | 0.079 | 4.853 | 5.131 | 4.941 | 4.555 | 2.25 |
Operating Expenses
| 121.76 | 127.085 | 111.76 | 79.36 | 65.847 | 41.575 | 39.365 | 39.814 | 36.907 | 30.08 | 34.429 |
Operating Income
| 21.779 | 79.613 | 69.793 | 51.93 | 38.313 | 53.622 | 46.88 | 26.94 | 12.556 | 7.009 | 22.079 |
Operating Income Ratio
| 0.081 | 0.213 | 0.246 | 0.259 | 0.212 | 0.337 | 0.33 | 0.241 | 0.153 | 0.118 | 0.234 |
Total Other Income Expenses Net
| 9.562 | 0.335 | -0.149 | -0.203 | 0.212 | 0.079 | 4.853 | 6.16 | 4.916 | 4.545 | 2.242 |
Income Before Tax
| 21.976 | 79.947 | 69.644 | 51.727 | 38.525 | 53.7 | 51.733 | 33.1 | 17.472 | 11.554 | 24.321 |
Income Before Tax Ratio
| 0.081 | 0.214 | 0.246 | 0.258 | 0.213 | 0.338 | 0.364 | 0.296 | 0.212 | 0.194 | 0.257 |
Income Tax Expense
| 3.531 | 0.261 | 6.114 | 3.341 | 4.118 | 5.486 | 6.745 | 4.084 | 2.1 | 1.432 | 2.865 |
Net Income
| 19.669 | 79.686 | 63.53 | 48.386 | 34.406 | 48.215 | 44.988 | 29.016 | 15.372 | 10.122 | 21.457 |
Net Income Ratio
| 0.073 | 0.213 | 0.224 | 0.242 | 0.19 | 0.303 | 0.317 | 0.26 | 0.187 | 0.17 | 0.227 |
EPS
| 0.18 | 0.74 | 0.59 | 0.45 | 0.32 | 0.6 | 0.55 | 0.36 | 0.21 | 0.48 | 0 |
EPS Diluted
| 0.17 | 0.71 | 0.59 | 0.45 | 0.32 | 0.6 | 0.55 | 0.36 | 0.21 | 0.48 | 0 |
EBITDA
| 35.164 | 93.372 | 80.738 | 61.276 | 46.457 | 58.272 | 49.811 | 30.105 | 19.524 | 13.013 | 23.437 |
EBITDA Ratio
| 0.13 | 0.25 | 0.285 | 0.306 | 0.257 | 0.366 | 0.351 | 0.269 | 0.237 | 0.219 | 0.248 |